{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:05:38Z","timestamp":1791266738396,"version":"4.1.0"},"reference-count":40,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T00:00:00Z","timestamp":1378339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Parasitology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>This review presents a progression strategy for the discovery of new anti-parasitic drugs that uses<jats:italic>in vitro<\/jats:italic>susceptibility, time-kill and reversibility measures to define the therapeutically relevant exposure required in target tissues of animal infection models. The strategy is exemplified by the discovery of SCYX-7158 as a potential oral treatment for stage 2 (CNS) Human African Trypanosomiasis (HAT). A critique of current treatments for stage 2 HAT is included to provide context for the challenges of achieving target tissue disposition and the need for establishing pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) measures early in the discovery paradigm. The strategy comprises 3 stages. Initially, compounds demonstrating promising<jats:italic>in vitro<\/jats:italic>activity and selectivity for the target organism over mammalian cells are advanced to<jats:italic>in vitro<\/jats:italic>metabolic stability, barrier permeability and tissue binding assays to establish that they will likely achieve and maintain therapeutic concentrations during in-life efficacy studies. Secondly,<jats:italic>in vitro<\/jats:italic>time-kill and reversibility kinetics are employed to correlate exposure (based on unbound concentrations) with<jats:italic>in vitro<\/jats:italic>activity, and to identify pharmacodynamic measures that would best predict efficacy. Lastly, this information is used to design dosing regimens for pivotal pharmacokinetic\u2013pharmacodyamic studies in animal infection models.<\/jats:p>","DOI":"10.1017\/s003118201300098x","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T12:35:09Z","timestamp":1378384509000},"page":"104-118","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":33,"title":["Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis"],"prefix":"10.1017","volume":"141","author":[{"given":"STEPHEN","family":"WRING","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ERIC","family":"GAUKEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BAKELA","family":"NARE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERT","family":"JACOBS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BETH","family":"BEAUDET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TANA","family":"BOWLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUKE","family":"MERCER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CYRUS","family":"BACCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NIGEL","family":"YARLETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RYAN","family":"RANDOLPH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBIN","family":"PARHAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CINDY","family":"REWERTS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACOB","family":"PLATNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERT","family":"DON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2013,9,5]]},"reference":[{"key":"S003118201300098X_ref36","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025001131513"},{"key":"S003118201300098X_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20166"},{"key":"S003118201300098X_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16940-7"},{"key":"S003118201300098X_ref29","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.149872"},{"key":"S003118201300098X_ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39485.592674.BE"},{"key":"S003118201300098X_ref26a","first-page":"1435","article-title":"Nifurtomox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping slickness: a randomized trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"CSE Theme Article, CID"},{"key":"S003118201300098X_ref26","first-page":"620","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"S003118201300098X_ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.369-377.2004"},{"key":"S003118201300098X_ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000079137"},{"key":"S003118201300098X_ref18","first-page":"82","volume-title":"Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring","author":"MacKichan","year":"2005"},{"key":"S003118201300098X_ref16","doi-asserted-by":"publisher","DOI":"10.2174\/138920008783331077"},{"key":"S003118201300098X_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2006.09.003"},{"key":"S003118201300098X_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(99)90151-7"},{"key":"S003118201300098X_ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001695"},{"key":"S003118201300098X_ref12","first-page":"147","article-title":"Relapsed parasitemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes","volume":"7","author":"Jennings","year":"1983","journal-title":"Contributions to Microbiology and Immunology"},{"key":"S003118201300098X_ref10","doi-asserted-by":"publisher","DOI":"10.1645\/GE-287R"},{"key":"S003118201300098X_ref28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood-brain barrier significantly limits eflornithine entry into the Trypanosoma brucei brucei infected Mouse Brain","volume":"107","author":"Sanderson","year":"2008","journal-title":"Journal of Neurochemistry"},{"key":"S003118201300098X_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706X(94)90120-1"},{"key":"S003118201300098X_ref35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923"},{"key":"S003118201300098X_ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001151"},{"key":"S003118201300098X_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2007.05.045"},{"key":"S003118201300098X_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.200"},{"key":"S003118201300098X_ref20","doi-asserted-by":"publisher","DOI":"10.1021\/jm010152k"},{"key":"S003118201300098X_ref22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00712.x"},{"key":"S003118201300098X_ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600415"},{"key":"S003118201300098X_ref32","first-page":"595","article-title":"In vitro prediction of brain penetration \u2013 a case for free thinking","volume":"1","author":"Summerfield","year":"2006","journal-title":"Expert Opinion"},{"key":"S003118201300098X_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.07.011"},{"key":"S003118201300098X_ref39","first-page":"69","volume":"81","year":"2006","journal-title":"Weekly Epidemiological Record"},{"key":"S003118201300098X_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(93)90044-Q"},{"key":"S003118201300098X_ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00498-10"},{"key":"S003118201300098X_ref9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1152\/ajplegacy.1959.196.2.420","article-title":"Circulating and tissue hematocrits of normal ananesthetized mic","volume":"196","author":"Friedman","year":"1959","journal-title":"American Journal of Physiology"},{"key":"S003118201300098X_ref2","doi-asserted-by":"publisher","DOI":"10.1373\/49.7.1041"},{"key":"S003118201300098X_ref33","first-page":"1282","article-title":"Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain","volume":"316","author":"Summerfield","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"key":"S003118201300098X_ref38","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022814"},{"key":"S003118201300098X_ref17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"S003118201300098X_ref1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1959.14.6.1005"},{"key":"S003118201300098X_ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00725.x"},{"key":"S003118201300098X_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.02.004"},{"key":"S003118201300098X_ref6","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1086\/429929","article-title":"Effectiveness of a 10-day Melarsoprol schedule for the treatment of late-stage Human African Trypanosomiasis: confirmation from a multinational study (IMPAMEL II)","volume":"191","author":"Doua","year":"2005","journal-title":"Journal of Infectious Diseases"},{"key":"S003118201300098X_ref7","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.015222"}],"container-title":["Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S003118201300098X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:11:36Z","timestamp":1715965896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S003118201300098X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S003118201300098X"],"URL":"https:\/\/doi.org\/10.1017\/s003118201300098x","relation":{},"ISSN":["0031-1820","1469-8161"],"issn-type":[{"value":"0031-1820","type":"print"},{"value":"1469-8161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,5]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2013\u00a0The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution license <http:\/\/creativecommons.org\/licenses\/by\/3.0\/>.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}